P
Prayura Kunasol
Researcher at Thailand Ministry of Public Health
Publications - 21
Citations - 4423
Prayura Kunasol is an academic researcher from Thailand Ministry of Public Health. The author has contributed to research in topics: Vaccination & Vaccine trial. The author has an hindex of 14, co-authored 21 publications receiving 4235 citations.
Papers
More filters
Journal ArticleDOI
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more
TL;DR: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk and offer insight for future research.
Journal ArticleDOI
Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases
TL;DR: Between 1989 and 1993 the use of condoms in commercial sex in Thailand increased from 14 to 94%, according to surveys of prostitutes, and the number of cases of the five major sexually transmitted diseases declined by 79% in men.
Journal ArticleDOI
Protection against hepatitis A by an inactivated vaccine.
Bruce L. Innis,Rapin Snitbhan,Prayura Kunasol,Thanom Laorakpongse,W. Poopatanakool,C. A. Kozik,Saroj Suntayakorn,Suknuntapong T,Assad Safary,Tang Db +9 more
TL;DR: Inactivated hepatitis A vaccine is safe; when administered in two doses, it protects against hepatitis A for at least 1 year and appears to have been partially protected since their illnesses were brief and associated with only slight increases in alanine aminotransferase.
Journal ArticleDOI
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
Merlin L. Robb,Supachai Rerks-Ngarm,Sorachai Nitayaphan,Punnee Pitisuttithum,Jaranit Kaewkungwal,Prayura Kunasol,Chirasak Khamboonruang,Prasert Thongcharoen,Patricia Morgan,Michael Benenson,Robert Paris,Joseph Chiu,Elizabeth Adams,Donald P. Francis,Sanjay Gurunathan,Jim Tartaglia,Peter B. Gilbert,Don Stablein,Nelson L. Michael,Jerome H. Kim,Jerome H. Kim +20 more
TL;DR: In this article, the authors performed a post-hoc analysis of the trial's data to investigate behavioural risk and efficacy every 6 months after vaccination, and found that the vaccine efficacy seemed to peak early and declined quickly.
Journal ArticleDOI
Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E
Supachai Rerks-Ngarm,Robert Paris,Supamit Chunsutthiwat,Nakorn Premsri,Chawetsan Namwat,Chureeratana Bowonwatanuwong,Shuying S. Li,Jaranit Kaewkungkal,Rapee Trichavaroj,Nampueng Churikanont,Mark de Souza,Charla Andrews,Donald P. Francis,Elizabeth Adams,Jorge Flores,Sanjay Gurunathan,Jim Tartaglia,Robert J. O'Connell,Chirapa Eamsila,Sorachai Nitayaphan,Viseth Ngauy,Prasert Thongcharoen,Prayura Kunasol,Nelson L. Michael,Merlin L. Robb,Peter B. Gilbert,Jerome H. Kim +26 more
TL;DR: Vaccination did not affect the clinical course of HIV disease after infection and a potential vaccine effect on the genital mucosa warrants further study.